Printer Friendly

Merck ceases development of evofosfamide.

M2 PHARMA-December 9, 2015-Merck ceases development of evofosfamide


United States-based Merck has decided to halt the development of evofosfamide for advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma, it was reported yesterday.

The company has taken this step after the drug candidate failed to meet its primary endpoints in two Phase III trials. The product failed to improve overall survival when integrated with chemotherapy in the two indications. It is an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe tumour hypoxic conditions.

The company acquired the rights to develop the product from Threshold Pharmaceuticals in February 2012.

((Comments on this story may be sent to

COPYRIGHT 2015 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 9, 2015
Previous Article:Celgene commence Fusion clinical development program for durvalumab with AstraZeneca.
Next Article:ERYTECH Pharma raises funds to expand programmes.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters